GYPA

Product List

Creative Biolabs is dedicated to supporting the development of anti-GYPA CAR-T therapy. We provide not only a comprehensive series of GYPA molecular-related CAR-T products but also customized CAR-T cell development services. Our extensive range of anti-GYPA CAR-T products and customized services enable researchers to advance their innovative treatments and make a significant impact on the field of CAR-T therapy.

Background

Glycophorins A (GYPA) and B (GYPB) are major sialoglycoproteins of the human erythrocyte membrane which bear the antigenic determinants for the MN and Ss blood groups. In addition to the M or N and S or s antigens that commonly occur in all populations, about 40 related variant phenotypes have been identified. These variants include all the variants of the Miltenberger complex and several isoforms of Sta, as well as Dantu, Sat, He, Mg, and deletion variants Ena, SsU, and Mk. Mutations in GYPA can lead to various forms of anemia and other symptoms, including sickle cell anemia and thalassemia. Moreover, GYPA mutations are associated with an increased susceptibility to certain types of malignancies.

Fig.1 Schematic of GYPA.¹

Associated Disease

Ovarian cancer

Colorectal cancer

Breast cancers

Prostate cancer

Lung cancer

Anti-GYPA CAR-T Services

Anti-GYPA CAR-T In Vitro Assays

Anti-GYPA CAR-T Expression Test

The Anti-GYPA CAR-T Expression Test is designed to monitor the expression of the anti-GYPA CAR-T receptor and its components in T cells. This test helps to ensure that the anti-GYPA CAR-T cells express the appropriate receptors and molecules at the correct levels, which is crucial for their function and survival. We analyze anti-GYPA CAR expression by different detection methods using flow cytometry, western blot, and qPCR.

Anti-GYPA CAR-T Proliferation Test

The Anti-GYPA CAR-T Proliferation Test evaluates the ability of anti-GYPA CAR-T cells to proliferate and expand in response to specific stimuli. This test is crucial for determining the potential of anti-GYPA CAR-T cells to generate a sufficient number of effector cells for therapeutic applications.

Anti-GYPA CAR-T Cytokine Release Test

The Anti-GYPA CAR-T Cytokine Release Test assesses the ability of anti-GYPA CAR-T cells to produce and release cytokines in response to specific stimuli. By measuring the level of cytokines released by anti-GYPA CAR-T cells, we can evaluate their immune-stimulating potential and assess their suitability and safety for use in therapeutic applications.

Anti-GYPA CAR-T In Vitro Cytotoxicity Assay

The Anti-GYPA CAR-T Cytotoxicity Test is designed to measure the ability of anti-GYPA CAR-T cells to target and eliminate cancer cells expressing GYPA. This test helps to evaluate the specificity and potency of anti-GYPA CAR-T cells against target cells. By analyzing the rate of target cell death induced by anti-GYPA CAR-T cells, we can assess the cytotoxic potential of these cells and ensure that they selectively target cancer cells without causing unnecessary harm to healthy tissues.

Anti-GYPA CAR-T In Vivo Assays

We provide in vivo assays to evaluate the therapeutic potential and safety of anti-GYPA CAR-T cells in a living organism. These assays typically involve the administration of anti-GYPA CAR-T cells to animal models, such as mice or rats, and monitoring their physiological and behavioral responses. By conducting these assays, we can determine the efficacy of anti-GYPA CAR-T cells in targeting specific diseases and assess any potential adverse effects.

Reference

1. Xia, Yi, and Ling Peng. "Photoactivatable lipid probes for studying biomembranes by photoaffinity labeling." Chemical reviews 113.10 (2013): 7880-7929.